{"id":55846,"date":"2023-04-14T18:05:42","date_gmt":"2023-04-14T16:05:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/"},"modified":"2023-04-14T18:05:42","modified_gmt":"2023-04-14T16:05:42","slug":"oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/","title":{"rendered":"Oxford Nanopore and bioM\u00e9rieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics"},"content":{"rendered":"
\n

OXFORD, England & MARCY-L\u2019ETOILE, France–(BUSINESS WIRE)–Oxford Nanopore Technologies plc (LSE: ONT) (\u201cOxford Nanopore\u201d), the company delivering a new generation of nanopore-based molecular sensing technology, and bioM\u00e9rieux SA, a world leader in the field of in vitro<\/i> diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.<\/b><\/p>\n

<\/a><\/p>\n

\nThe companies are jointly exploring selected opportunities to advance patient care by providing access to nanopore-based clinical research and in vitro<\/i> diagnostic (IVD) solutions.<\/p>\n

\nNanopore-based sequencing is a novel technology that enables analysis of long DNA or RNA fragments. It works by monitoring changes to an electrical current as nucleic acids are passed through a protein nanopore. The resulting signal is decoded to provide the specific DNA or RNA sequence. The unique real-time, scalable features of this technology make it ideal for the rapid and cost-effective characterization of pathogens in clinical samples.<\/p>\n

\nOffering rapid and accurate identification of microbial pathogens and associated antimicrobial resistance, Oxford Nanopore is uniquely positioned to deliver nanopore-based sequencing solutions that provide comprehensive results and reduce time to results for infectious diseases research and diagnostic applications.<\/p>\n

\nInitial areas of collaboration will include a test for determining antibiotic resistance of tuberculosis; an assay to identify pathogens in normally sterile clinical samples; and validating Oxford Nanopore’s sequencing platform with BIOM\u00c9RIEUX EPISEQ\u00ae<\/sup> CS application for rapid infection outbreak monitoring in patient-care settings.<\/p>\n

\nGordon Sanghera, Oxford Nanopore Technologies Chief Executive Officer, commented:<\/b> \u201cWe are pleased to partner with bioM\u00e9rieux\u2019s IVD expertise to add powerful new tools for the fight against infectious disease. By offering rapid and accurate identification of pathogens and associated antimicrobial resistance, at scale, we hope to better equip the specialists for whom speed and access to comprehensive data is key.\u201d<\/i><\/p>\n

\nAlexandre M\u00e9rieux, bioM\u00e9rieux Chairman and CEO, commented:<\/b> \u201cWe are excited to enter into a research partnership with Oxford Nanopore in the field of infectious diseases. New technologies such as sequencing hold promise to improve diagnostics and patient care; our teams will collaborate in this direction.\u201d<\/i><\/p>\n

\nAbout bioM\u00e9rieux:<\/b><\/p>\n

\nPIONEERING DIAGNOSTICS<\/p>\n

\nA world leader in the field of in vitro<\/i> diagnostics since 1963, bioM\u00e9rieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2022, revenues reached \u20ac3.6 billion, with over 90% of sales outside of France. bioM\u00e9rieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products. Learn more: www.biomerieux.com<\/a><\/p>\n\n\n
\n

\nbioM\u00e9rieux is listed on the Euronext Paris stock market.<\/p>\n

\nSymbol: BIM \u2013 ISIN Code: FR0013280286<\/p>\n

\nReuters: BIOX.PA\/Bloomberg: BIM.FP<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAbout Oxford Nanopore Technologies<\/b><\/p>\n

\nOxford Nanopore Technologies\u2019 goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. www.nanoporetech.com<\/a><\/p>\n

\nForward-looking statements<\/b><\/p>\n

\nThis announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as “aim”, “plan”, \u201cexpect\u201d, “intend”, “anticipate”, “believe”, “estimate”, “target”, and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, the COVID-19 pandemic, delays in our receipt of components or our delivery of products to our customers, suspensions of large projects and\/or acceleration of large products or accelerated adoption of pathogen surveillance. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.<\/p>\n

Contacts<\/b> <\/p>\n

\nOxford Nanopore<\/span><\/i><\/b>
Media Relations<\/b>
media@nanoporetech.com<\/a>
Investors Relations<\/b>
ir@nanoporetech.com<\/a><\/p>\n

\nTeneo (communication adviser to the Company)<\/b>
Tom Murray, Olivia Peters
\n
Tel.: +44 (0) 20 7353 4200
\n
OxfordNanoporeTechnologies@teneo.com<\/a><\/p>\n

\nbioM\u00e9rieux<\/span><\/i><\/b>
Media Relations<\/b>
Romain Duchez
\n
Tel.: +33 (0)4 78 87 21 99
\n
media@biomerieux.com<\/a><\/p>\n

\nInvestors Relations<\/b>
Franck Admant
\n
Tel.: +33 (0)4 78 87 20 00
\n
investor.relations@biomerieux.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

OXFORD, England & MARCY-L\u2019ETOILE, France–(BUSINESS WIRE)–Oxford Nanopore Technologies plc (LSE: ONT) (\u201cOxford Nanopore\u201d), the company delivering a new generation of nanopore-based molecular sensing technology, and bioM\u00e9rieux SA, a world leader in the field of in vitro diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55846","6":"format-standard","7":"category-industry"},"yoast_head":"\nOxford Nanopore and bioM\u00e9rieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oxford Nanopore and bioM\u00e9rieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"OXFORD, England & MARCY-L\u2019ETOILE, France–(BUSINESS WIRE)–Oxford Nanopore Technologies plc (LSE: ONT) (\u201cOxford Nanopore\u201d), the company delivering a new generation of nanopore-based molecular sensing technology, and bioM\u00e9rieux SA, a world leader in the field of in vitro diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-14T16:05:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230414005303\/en\/1764176\/21\/ONT_logo_RGB%5B93%5D.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Oxford Nanopore and bioM\u00e9rieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics\",\"datePublished\":\"2023-04-14T16:05:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/\"},\"wordCount\":762,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230414005303\\\/en\\\/1764176\\\/21\\\/ONT_logo_RGB%5B93%5D.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/\",\"name\":\"Oxford Nanopore and bioM\u00e9rieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230414005303\\\/en\\\/1764176\\\/21\\\/ONT_logo_RGB%5B93%5D.jpg\",\"datePublished\":\"2023-04-14T16:05:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230414005303\\\/en\\\/1764176\\\/21\\\/ONT_logo_RGB%5B93%5D.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230414005303\\\/en\\\/1764176\\\/21\\\/ONT_logo_RGB%5B93%5D.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oxford Nanopore and bioM\u00e9rieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oxford Nanopore and bioM\u00e9rieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/","og_locale":"en_US","og_type":"article","og_title":"Oxford Nanopore and bioM\u00e9rieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics - Pharma Trend","og_description":"OXFORD, England & MARCY-L\u2019ETOILE, France–(BUSINESS WIRE)–Oxford Nanopore Technologies plc (LSE: ONT) (\u201cOxford Nanopore\u201d), the company delivering a new generation of nanopore-based molecular sensing technology, and bioM\u00e9rieux SA, a world leader in the field of in vitro diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-14T16:05:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230414005303\/en\/1764176\/21\/ONT_logo_RGB%5B93%5D.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Oxford Nanopore and bioM\u00e9rieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics","datePublished":"2023-04-14T16:05:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/"},"wordCount":762,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230414005303\/en\/1764176\/21\/ONT_logo_RGB%5B93%5D.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/","url":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/","name":"Oxford Nanopore and bioM\u00e9rieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230414005303\/en\/1764176\/21\/ONT_logo_RGB%5B93%5D.jpg","datePublished":"2023-04-14T16:05:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230414005303\/en\/1764176\/21\/ONT_logo_RGB%5B93%5D.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230414005303\/en\/1764176\/21\/ONT_logo_RGB%5B93%5D.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/oxford-nanopore-and-biomerieux-to-enter-into-a-strategic-partnership-agreement-to-develop-innovative-infectious-disease-diagnostics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Oxford Nanopore and bioM\u00e9rieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55846","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55846"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55846\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}